Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, including women with chemotherapy-induced ovarian failure, those treated with aromatase inhibitors for breast cancer, men receiving androgen-deprivation therapy for prostate cancer, and patients undergoing glucocorticoid therapy. The skeleton is a common site of metastatic cancer recurrence, and skeletal-related events are the cause of significant morbidity. The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force on Bone Health in Cancer Care to discuss the progress made in identifying effective screening and therapeutic options for management of treatment-related bone loss; understanding the factors that result in bone metastases; managing skeletal metastases; and evolving strategies to reduce bone recurrences. This report summarizes presentations made at the meeting.
MohlerJ, AmlingCL, BahnsonRR et al.. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, version 2.2009.Available at: http://www.nccn.org. Last accessed 8 June 2009.
MohlerJAmlingCLBahnsonRR. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, version 2.2009. Available at: http://www.nccn.org. Last accessed 8 June 2009.
)| false
CarlsonRW, AllredDC, AndersonBO et al.. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version I.2009.Available at: http://www.nccn.org. Last accessed 8 June 2009.
CarlsonRWAllredDCAndersonBO. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version I.2009. Available at: http://www.nccn.org. Last accessed 8 June 2009.
)| false
U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med2002;137:526–528.
U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137:526–528.
12230355)| false
HillnerBE, IngleJN, ChlebowskiRT et al.. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol2003;21:4042–4057.
HillnerBEIngleJNChlebowskiRT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057.
)| false
World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX WHO fracture risk assessment tool. Available at: http://www.shef.ac.uk/FRAX/. Accessed May 31, 2009.
World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX WHO fracture risk assessment tool. Available at: http://www.shef.ac.uk/FRAX/. Accessed May 31, 2009.
)| false
GarneroP, DelmasPD. Biochemical markers of bone turnover in osteoporosis. In: MarcusM, FeldmanD, KelseyJ. eds. Osteoporosis. Vol 2. Academic Press; New York;459–477.
GarneroPDelmasPD. Biochemical markers of bone turnover in osteoporosis. In: MarcusMFeldmanDKelseyJ. eds. Osteoporosis. Vol 2. Academic Press; New York;459–477.
)| false
GarneroP, Sornay-RenduE, ClaustratB, DelmasPD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res2000;15:1526–1536.
GarneroPSornay-RenduEClaustratBDelmasPD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526–1536.
10934651)| false
RossPD, KressBC, ParsonRE et al.. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int2000;11:76–82.
RossPDKressBCParsonRE. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000;11:76–82.
10663362)| false
Sornay-RenduE, MunozF, GarneroP et al.. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res2005;20:1813–1819.
Sornay-RenduEMunozFGarneroP. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20:1813–1819.
16160738)| false
ChristgauS, Bitsch-JensenO, Hanover BjarnasonN et al.. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone2000;26:505–511.
ChristgauSBitsch-JensenOHanover BjarnasonN. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000;26:505–511.
10773591)| false
EastellR, MallinakN, WeissS et al.. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res2000;15:594–598.
EastellRMallinakNWeissS. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15:594–598.
10750575)| false
ClowesJA, HannonRA, YapTS et al.. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone2002;30:886–890.
ClowesJAHannonRAYapTS. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886–890.
)| false
BlackDM, ArdenNK, PalermoL et al.. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res1999;14:821–828.
BlackDMArdenNKPalermoL. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:821–828.
10320531)| false
Physicians guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation guideline.Belle Mead, NJ:Excerpta Medica, Inc;1999.
Physicians guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation guideline. Belle Mead, NJ:Excerpta Medica, Inc;1999.
)| false
FeskanichDWillettWColditzG. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002;288:2300–2306.
12425707)| false
Centers for Disease Control and Prevention. Fatalities and injuries from falls among older adults—United States, 1993-2003 and 2001-2005. MMWR Morb Mortal Wkly Rep2006;55:1221–1224.
Centers for Disease Control and Prevention. Fatalities and injuries from falls among older adults—United States, 1993-2003 and 2001-2005. MMWR Morb Mortal Wkly Rep 2006;55:1221–1224.
17108890)| false
TinettiME, WilliamsCS. The effect of falls and fall injuries on functioning in community-dwelling older persons. J Gerontol A Biol Sci Med Sci1998;53:M112–M119.
TinettiMEWilliamsCS. The effect of falls and fall injuries on functioning in community-dwelling older persons. J Gerontol A Biol Sci Med Sci 1998;53:M112–M119.
9520917)| false
National Osteoporosis Foundation. Patient info: fall prevention.Available at: http://www.nof.org/patientinfo/fall_prevention.htm. Accessed May 2009.
National Osteoporosis Foundation. Patient info: fall prevention. Available at: http://www.nof.org/patientinfo/fall_prevention.htm. Accessed May 2009.
)| false
ParkerMJ, GillespieWJ, GillespieLD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ2006;332:571–574.
ParkerMJGillespieWJGillespieLD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 2006;332:571–574.
16513687)| false
SawkaAM, BoulosP, BeattieK et al.. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J Clin Epidemiol2007;60:336–344.
SawkaAMBoulosPBeattieK. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J Clin Epidemiol 2007;60:336–344.
17346606)| false
Dawson-HughesB, HarrisSS, KrallEA, DallalGE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med1997;337:670–676.
Dawson-HughesBHarrisSSKrallEADallalGE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670–676.
)| false
National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: calcium.Available at: http://ods.od.nih.gov/factsheets/calcium.asp. Accessed May 2009.
National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: calcium. Available at: http://ods.od.nih.gov/factsheets/calcium.asp. Accessed May 2009.
)| false
National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: vitamin D.Available at: http://ods.od.nih.gov/factsheets/vitamind.asp. Accessed May 2009.
National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: vitamin D. Available at: http://ods.od.nih.gov/factsheets/vitamind.asp. Accessed May 2009.
)| false
Office of the Surgeon General. Bone health and osteoporosis: a report of the surgeon general. Issued October 14, 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth/index.html. Accessed May 2009.
Office of the Surgeon General. Bone health and osteoporosis: a report of the surgeon general. Issued October 14, 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth/index.html. Accessed May 2009.
)| false
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride.Washington, DC; National Academy Press; 1997.
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC; National Academy Press; 1997.
)| false
CurhanGC, WillettWC, SpeizerFE et al.. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med1997;126:497–504.
CurhanGCWillettWCSpeizerFE. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997;126:497–504.
9092314)| false
AdamsJS, KantorovichV, WuC et al.. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab1999;84:2729–2730.
AdamsJSKantorovichVWuC. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab 1999;84:2729–2730.
10443668)| false
CranneyC, HorselyT, O’DonnellS et al.. Effectiveness and safety of vitamin D. Evidence Report/Technology Assessment No. 158 AHRQ Publication No. 07-E013.Rockville: Agency for Healthcare Research and Quality; 2007.
CranneyCHorselyTO’DonnellS. Effectiveness and safety of vitamin D. Evidence Report/Technology Assessment No. 158 AHRQ Publication No. 07-E013. Rockville: Agency for Healthcare Research and Quality; 2007.
)| false
HolickMF, BiancuzzoRM, ChenTC et al.. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab2008;93:677–681.
HolickMFBiancuzzoRMChenTC. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008;93:677–681.
18089691)| false
MacLeanC, NewberryS, MaglioneM et al.. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med2008;148:197–213.
MacLeanCNewberrySMaglioneM. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197–213.
)| false
SmithMR, EasthamJ, GleasonDM et al.. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003;169:2008–2012.
SmithMREasthamJGleasonDM. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008–2012.
12771706)| false
SmithMR, McGovernFJ, ZeitmanAL et al.. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med2001;345:948–955.
SmithMRMcGovernFJZeitmanAL. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–955.
11575286)| false
TauchmanovaL, ColaoA, LombardiG et al.. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab2007;92:4536–4545.
TauchmanovaLColaoALombardiG. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab 2007;92:4536–4545.
17911175)| false
RossouwJE, AndersonGL, PrenticeRL et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA2002;288:321–333.
RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
12117397)| false
Van PoznakCEstiloC. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park) 2006;20:1053–1062.
16986349)| false
KhoslaS, BurrD, CauleyJ et al.. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res2007;22:1479–1491.
KhoslaSBurrDCauleyJ. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–1491.
17663640)| false
WooSBHellsteinJWKalmarJR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753–761.
16702591)| false
BrufskyA, BundredN, ColemanR et al.. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist2008;13:503–514.
BrufskyABundredNColemanR. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008;13:503–514.
18515735)| false
GnantMF, MlineritschB, Luschin-EbengreuthG et al.. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol2007;25:820–828.
GnantMFMlineritschBLuschin-EbengreuthG. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820–828.
)| false
WeitzmanR, SauterN, EriksenEF et al.. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol2007;62:148–152.
WeitzmanRSauterNEriksenEF. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol 2007;62:148–152.
17336086)| false
LylesKWColon-EmericCSMagazinerJS. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799–1809.
17878149)| false
U.S. Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of biophosphonates. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm. Accessed May 2009.
U.S. Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of biophosphonates. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm. Accessed May 2009.
)| false
GohSK, YangKY, KohJS et al.. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br2007;89:349–353.
GohSKYangKYKohJS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349–353.
17356148)| false
KwekEB, GohSK, KohJS et al.. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?Injury2008;39:224–231.
KwekEBGohSKKohJS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?Injury 2008;39:224–231.
18222447)| false
HolmbergL, AndersonH. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet2004;363:453–455.
HolmbergLAndersonH. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453–455.
)| false
Christin-MaitreS. The role of hormone replacement therapy in the management of premature ovarian failure. Nat Clin Pract Endocrinol Metab 2008;4:60–61.
18030288)| false
EttingerB, BlackDM, MitlakBH et al.. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA1999;282:637–645.
EttingerBBlackDMMitlakBH. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645.
10517716)| false
Barrett-ConnorE, MoscaL, CollinsP et al.. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med2006;355:125–137.
Barrett-ConnorEMoscaLCollinsP. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–137.
16837676)| false
MartinoS, CauleyJA, Barrett-ConnorE et al.. Continuing outcomes relevant to EVISTA: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst2004;96:1751–1761.
MartinoSCauleyJABarrett-ConnorE. Continuing outcomes relevant to EVISTA: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–1761.
)| false
VogelVG, CostantinoJP, WickerhamDL et al.. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA2006;295:2727–2741.
VogelVGCostantinoJPWickerhamDL. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727–2741.
16754727)| false
CauleyJA, NortonL, LippmanME et al.. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat2001;65:125–134.
CauleyJANortonLLippmanME. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 2001;65:125–134.
11261828)| false
O’ReganRM, GajdosC, DardesRC et al.. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst2002;94:274–283.
O’ReganRMGajdosCDardesRC. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002;94:274–283.
11854389)| false
StewartHJ, ForrestAP, EveringtonD et al.. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer1996;74:297–299.
StewartHJForrestAPEveringtonD. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996;74:297–299.
8688340)| false
Eng-WongJ, ReynoldsJC, VenzonD et al.. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab2006;91:3941–3946.
Eng-WongJReynoldsJCVenzonD. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006;91:3941–3946.
)| false
BaumM, BuzdarA, CuzickJ et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer2003;98:1802–1810.
BaumMBuzdarACuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–1810.
14584060)| false
GossP, BondarenkoIN, ManikhasGN et al.. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol2007;25:4961–4966.
GossPBondarenkoINManikhasGN. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol 2007;25:4961–4966.
17971594)| false
CummingsSR, McClungMR, ChristiansenC et al.. A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 1286.
CummingsSRMcClungMRChristiansenC. A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 1286.
)| false
BrownJP, DealC, de GregorinLH et al.. Effect of densoumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 1285.
BrownJPDealCde GregorinLH. Effect of densoumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 1285.
)| false
KendlerDL, BenhamouCL, BrownJP et al.. Effects of denosumab vs. alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 138.
KendlerDLBenhamouCLBrownJP. Effects of denosumab vs. alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate [abstract]. Presented at the American Society of Bone and Mineral Research 30th Annual Meeting; September 12–16, 2008; Montreal, Quebec, Canada. Abstract 138.
)| false
ChesnutCHIII, BellNH, ClarkGS et al.. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med1997;102:29–37.
ChesnutCHIIIBellNHClarkGS. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29–37.
9209198)| false
RavnP, ClemmesenB, ChristiansenC. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone1999;24:237–244.
RavnPClemmesenBChristiansenC. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24:237–244.
)| false
ToninoRP, MeunierPJ, EmkeyR et al.. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab2000;85:3109–3115.
ToninoRPMeunierPJEmkeyR. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85:3109–3115.
)| false
BlackDM, SchwartzAV, EnsrudKE et al.. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA2006;296:2927–2938.
BlackDMSchwartzAVEnsrudKE. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–2938.
17190893)| false
FornierMN, ModiS, PanageasKS et al.. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer2005;104:1575–1579.
FornierMNModiSPanageasKS. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104:1575–1579.
16134178)| false
PetrekJA, NaughtonMJ, CaseLD et al.. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol2006;24:1045–1051.
PetrekJANaughtonMJCaseLD. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045–1051.
16476708)| false
ShapiroCL, ManolaJ, LeboffM. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol2001;19:3306–3311.
ShapiroCLManolaJLeboffM. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306–3311.
11454877)| false
HeadleyJA, TheriaultRL, LeBlancAD et al.. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest1998;16:6–11.
HeadleyJATheriaultRLLeBlancAD. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 1998;16:6–11.
9474245)| false
PowlesTJ, McCloskeyE, PatersonAH et al.. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst1998;90:704–708.
PowlesTJMcCloskeyEPatersonAH. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998;90:704–708.
9586668)| false
SaartoT, BlomqvistC, ValimakiM et al.. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol1997;15:1341–1347.
SaartoTBlomqvistCValimakiM. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341–1347.
9193325)| false
HershmanDL, McMahonDJ, CrewKD et al.. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol2008;26:4739–4745.
HershmanDLMcMahonDJCrewKD. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008;26:4739–4745.
18711172)| false
DelmasPD, BalenaR, ConfravreuxE et al.. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol1997;15:955–962.
DelmasPDBalenaRConfravreuxE. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997;15:955–962.
9060533)| false
WarmingLHassagerCChristiansenC. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002;13:105–112.
11905520)| false
EastellR, HannonRA, CuzickJ et al.. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res2006;21:1215–1223.
EastellRHannonRACuzickJ. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215–1223.
)| false
FogelmanI, BlakeGM, BlameyR et al.. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int2003;14:1001–1006.
FogelmanIBlakeGMBlameyR. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14:1001–1006.
)| false
HershmanDL, McMahonDJ, CrewKD et al.. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol2008;26:4739–4745.
HershmanDLMcMahonDJCrewKD. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008;26:4739–4745.
18711172)| false
RippsBA, VanGilderK, MinhasB et al.. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med2003;48:761–766.
RippsBAVanGilderKMinhasB. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med 2003;48:761–766.
14619641)| false
GeislerJ, LonningPE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol2005;95:75–81.
GeislerJLonningPE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol 2005;95:75–81.
15975785)| false
BodyJJ, BergmannP, BoonenS et al.. Management of cancer treatment-induced bone loss in early breast and prostate cancer—a consensus paper of the Belgian Bone Club. Osteoporos Int2007;18:1439–1450.
BodyJJBergmannPBoonenS. Management of cancer treatment-induced bone loss in early breast and prostate cancer—a consensus paper of the Belgian Bone Club. Osteoporos Int 2007;18:1439–1450.
17690930)| false
ForbesJF, CuzickJ, BuzdarA et al.. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol2008;9:45–53.
ForbesJFCuzickJBuzdarA. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53.
18083636)| false
ThurlimannB, KeshaviahA, CoatesAS et al.. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med2005;353:2747–2757.
ThurlimannBKeshaviahACoatesAS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757.
16382061)| false
CoombesRC, HallE, GibsonLJ et al.. Intergroup Exemestane Study: a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:1081–1092.
CoombesRCHallEGibsonLJ. Intergroup Exemestane Study: a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.
15014181)| false
ColemanRE, BanksLM, GirgisSI et al.. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol2007;8:119–127.
ColemanREBanksLMGirgisSI. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119–127.
17267326)| false
National Cancer Institute. Phase III randomized adjuvant study of exemestane versus anastrozole in postmenopausal women receptor-positive primary breast cancer. Available at: http://www.cancer.gov/clinicaltrials/CAN-NCIC-MA27. Last accessed 8 June 2009.
National Cancer Institute. Phase III randomized adjuvant study of exemestane versus anastrozole in postmenopausal women receptor-positive primary breast cancer. Available at: http://www.cancer.gov/clinicaltrials/CAN-NCIC-MA27. Last accessed 8 June 2009.
)| false
GossPE, IngleJN, MartinoS et al.. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:1793–1802.
GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.
14551341)| false
ColemanRE. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial [abstract]. J Clin Oncol2006;24(Suppl 1):5s. Abstract 511.
ColemanRE. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial [abstract]. J Clin Oncol 2006;24(Suppl 1):5s. Abstract 511.
)| false
Van PoznakC, HannonRA, ClackG et al.. The SABRE study: effects of risedronate on bone mineral density and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early stage breast cancer—first results [abstract]. Breast Cancer Res Treat2006;100(Suppl 1):Abstract 4061.
Van PoznakCHannonRAClackG. The SABRE study: effects of risedronate on bone mineral density and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early stage breast cancer—first results [abstract]. Breast Cancer Res Treat 2006;100(Suppl 1):Abstract 4061.
)| false
Van PoznakC, HannonR, ClackG et al.. Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). San Antonio Breast Cancer symposium, Abstract 1137.
Van PoznakCHannonRClackG. Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). San Antonio Breast Cancer symposium, Abstract 1137.
)| false
LesterJE, GutcherSA, EllisS et al.. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 554.
LesterJEGutcherSAEllisS. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 554.
)| false
BundredNJ, CampbellID, DavidsonN et al.. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving letrozole: ZO-FAST study results. Cancer2008;112:1001–1010.
BundredNJCampbellIDDavidsonN. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving letrozole: ZO-FAST study results. Cancer 2008;112:1001–1010.
18205185)| false
SchenkN, LlombartA et al.. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole [abstract]. Presented at the 14th European Cancer Conference; September 23–27, 2007; Barcelona, Spain. Abstract 2008.
SchenkNLlombartA. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole [abstract]. Presented at the 14th European Cancer Conference; September 23–27, 2007; Barcelona, Spain. Abstract 2008.
)| false
EllisGK, BoneHG, ChlebowskiR et al.. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol2008;26:4875–4882.
KhoslaS, MeltonLJIII, AtkinsonEJ, O’FallonWM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab2001;86:3555–3561.
KhoslaSMeltonLJIIIAtkinsonEJO’FallonWM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001;86:3555–3561.
11502778)| false
MellstromD, VandenputL, MallminH et al.. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res2008;23:1552–1560.
MellstromDVandenputLMallminH. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008;23:1552–1560.
18518773)| false
SmithMR, LeeWC, BrandmanJ et al.. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol2005;23:7897–7903.
SmithMRLeeWCBrandmanJ. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–7903.
)| false
MittanD, LeeS, MillerE et al.. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab2002;87:3656–3661.
MittanDLeeSMillerE. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656–3661.
12161491)| false
MaillefertJF, SibiliaJ, MichelF et al.. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol1999;161:1219–1222.
MaillefertJFSibiliaJMichelF. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219–1222.
10081873)| false
DiamondT, CampbellJ, BryantC, LynchW. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer1998;83:1561–1566.
DiamondTCampbellJBryantCLynchW. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83:1561–1566.
)| false
BerrutiA, DogliottiL, TerroneC et al.. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol2002;167:2361–2367; discussion 2367.
BerrutiADogliottiLTerroneC. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361–2367; discussion 2367.
11992038)| false
SmithMR, McGovernFJ, ZietmanAL et al.. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med2001;345:948–955.
SmithMRMcGovernFJZietmanAL. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001;345:948–955.
11575286)| false
SmithMR, EasthamJ, GleasonD et al.. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003;169:2008–2012.
SmithMREasthamJGleasonD. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008–2012.
)| false
MichaelsonMD, KaufmanDS, LeeH et al.. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol2007;25:1038–1042.
MichaelsonMDKaufmanDSLeeH. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038–1042.
17369566)| false
GreenspanSL, NelsonJB, TrumpDL, ResnickNM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med2007;146:416–424.
GreenspanSLNelsonJBTrumpDLResnickNM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416–424.
)| false
SmithMR, FallonMA, LeeH, FinkelsteinJS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab2004;89:3841–3846.
SmithMRFallonMALeeHFinkelsteinJS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841–3846.
15292315)| false
SmithMR, MalkowiczSB, ChuF et al.. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase III clinical study. J Urol2008;179:152–155.
SmithMRMalkowiczSBChuF. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase III clinical study. J Urol 2008;179:152–155.
18001802)| false
SmithMR, MalkowiczSB, ChuF et al.. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol2008;26:1824–1829.
SmithMRMalkowiczSBChuF. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008;26:1824–1829.
18398147)| false
SenaratneSG, MansiJL, ColstonKW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer2002;86:1479–1486.
SenaratneSGMansiJLColstonKW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479–1486.
11986784)| false
van der PluijmG, VloedgravenH, van BeekE et al.. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest1996;98:698–705.
van der PluijmGVloedgravenHvan BeekE. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698–705.
8698861)| false
BoissierS, FerrerasM, PeyruchaudO et al.. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res2000;60:2949–2954.
BoissierSFerrerasMPeyruchaudO. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949–2954.
10850442)| false
TeronenO, KonttinenYT, SaloT et al.. [Bisphosphonates inhibit matrix metalloproteinases—a new possible mechanism of action]. Duodecim1999;115:13–15[in Finnish].
TeronenOKonttinenYTSaloT. [Bisphosphonates inhibit matrix metalloproteinases—a new possible mechanism of action]. Duodecim 1999;115:13–15[in Finnish].
11830856)| false
BoissierS, MagnettoS, FrappartL et al.. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res1997;57:3890–3894.
BoissierSMagnettoSFrappartL. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890–3894.
9307266)| false
SasakiA, BoyceBF, StoryB et al.. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res1995;55:3551–3557.
SasakiABoyceBFStoryB. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995;55:3551–3557.
7627963)| false
PowlesT, PatersonA, McCloskeyE et al.. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res2006;8:R13.
PowlesTPatersonAMcCloskeyE. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8:R13.
16542503)| false
DielIJSolomayerEFCostaSD. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New Engl J Med 1998;339:357–363.
9691101)| false
DielIJ, JaschkeA, SolomayerEF et al.. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol2008;19:2007–2011.
DielIJJaschkeASolomayerEF. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;19:2007–2011.
)| false
SaartoT, BlomqvistC, VirkkunenP, ElomaaI. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol2001;19:10–17.
SaartoTBlomqvistCVirkkunenPElomaaI. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10–17.
)| false
SmithMR, KabbinavarF, SaadF et al.. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol2005;23:2918–2925.
SmithMRKabbinavarFSaadF. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918–2925.
15860850)| false
MasonMD, SydesMR, GlaholmJ et al.. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst2007;99:765–776.
MasonMDSydesMRGlaholmJ. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007;99:765–776.
17505072)| false
RoudierMP, VesselleH, TrueLD et al.. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis2003;20:171–180.
RoudierMPVesselleHTrueLD. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003;20:171–180.
)| false
GuiseTAMohammadKSClinesG. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s–6216s.
17062703)| false
WithamTF, KhavkinYA, GalliaGL et al.. Surgery insight: current management of epidural spinal cord compression from metastatic spine disease. Nat Clin Pract Neurol2006;2:87–94; quiz 116.
TheriaultRL, LiptonA, HortobagyiGN et al.. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol1999;17:846–854.
TheriaultRLLiptonAHortobagyiGN. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846–854.
)| false
HortobagyiGN, TheriaultRL, PorterL et al.. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med1996;335:1785–1791.
HortobagyiGNTheriaultRLPorterL. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785–1791.
)| false
RosenLS, GordonD, KaminskiM et al.. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;7:377–387.
RosenLSGordonDKaminskiM. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–387.
)| false
KohnoN, AogiK, MinamiH et al.. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol2005;23:3314–3321.
KohnoNAogiKMinamiH. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314–3321.
15738536)| false
BodyJJ, DielIJ, LichinitzerM et al.. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer2004;90:1133–1137.
BodyJJDielIJLichinitzerM. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133–1137.
15026791)| false
Tubiana-HulinM, BeuzebocP, MauriacL et al.. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer2001;88:701–707[in French].
Tubiana-HulinMBeuzebocPMauriacL. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer 2001;88:701–707[in French].
11495824)| false
DielIJ, BodyJJ, LichinitserMR et al.. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer2004;40:1704–1712.
DielIJBodyJJLichinitserMR. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704–1712.
15251160)| false
BodyJJ, DielIJ, BellR et al.. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain2004;111:306–312.
BodyJJDielIJBellR. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306–312.
15363874)| false
LiptonA, TheriaultRL, HortobagyiGN et al.. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer2000;88:1082–1090.
LiptonATheriaultRLHortobagyiGN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082–1090.
10699899)| false
SaadF, GleasonDM, MurrayR et al.. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst2004;96:879–882.
SaadFGleasonDMMurrayR. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879–882.
15173273)| false
KyleRA, YeeGC, SomerfieldMR et al.. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol2007;25:2464–2472.
KyleRAYeeGCSomerfieldMR. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464–2472.
)| false
AaproM, AbrahamssonPA, BodyJJ et al.. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol2008;19:420–432.
AaproMAbrahamssonPABodyJJ. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420–432.
)| false
MajorP, LortholaryA, HonJ et al.. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558–567.
MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–567.
11208851)| false
RosenLS, GordonD, KaminskiM et al.. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer2003;98:1735–1744.
RosenLSGordonDKaminskiM. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735–1744.
)| false
KohnoN, AogiK, MinamiH et al.. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol2005;23:3314–3321.
KohnoNAogiKMinamiH. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314–3321.
15738536)| false
DearnaleyDP, SydesMR, MasonMD et al.. A double-blind, placebo-controlled, randomized trial of sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst2003;95:1300–1311.
DearnaleyDPSydesMRMasonMD. A double-blind, placebo-controlled, randomized trial of sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst 2003;95:1300–1311.
12953084)| false
ErnstDS, TannockIF, WinquistEW et al.. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol2003;21:3335–3342.
ErnstDSTannockIFWinquistEW. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335–3342.
12947070)| false
SmallEJ, SmithMR, SeamanJJ et al.. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol2003;21:4277–4284.
SmallEJSmithMRSeamanJJ. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277–4284.
14581438)| false
SaadF, GleasonDM, MurrayR et al.. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst2002;94:1458–1468.
SaadFGleasonDMMurrayR. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458–1468.
12359855)| false
ClinicalTrials.gov. Study to evaluate zoledronic acid on quality of life and skeletal-related events as adjuvant treatment in patients with hormone-naïve prostate cancer and bone metastasis who have undergone orchiectomy. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00237146?term=hormone+naive+prostate+cancer&rank=4. Accessed May 2009.
ClinicalTrials.gov. Study to evaluate zoledronic acid on quality of life and skeletal-related events as adjuvant treatment in patients with hormone-naïve prostate cancer and bone metastasis who have undergone orchiectomy. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00237146?term=hormone+naive+prostate+cancer&rank=4. Accessed May 2009.
)| false
ClinicalTrials.gov. Double-blind study of denosumab compared with zoledronic acid in the treatment of bone metastases in men with hormone-refractory prostate cancer. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00321620?term=denosumab+and+prostate+cancer&rank=2. Accessed May 2009.
ClinicalTrials.gov. Double-blind study of denosumab compared with zoledronic acid in the treatment of bone metastases in men with hormone-refractory prostate cancer. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00321620?term=denosumab+and+prostate+cancer&rank=2. Accessed May 2009.
)| false
FizaziK, LiptonA, MarietteX et al.. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol2009;27:1564–1571.
FizaziKLiptonAMarietteX. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564–1571.
)| false
LiptonA, StegerGG, FigueroaJ et al.. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol2007;25:4431–4437.
LiptonAStegerGGFigueroaJ. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431–4437.
17785705)| false
ClinicalTrials.gov. Dasatinib in treating patients with stage IV breast cancer that has spread to the bone. Available at: http://clinicaltrials.gov/ct2/show/NCT00410813. Accessed May 2009.
ClinicalTrials.gov. Dasatinib in treating patients with stage IV breast cancer that has spread to the bone. Available at: http://clinicaltrials.gov/ct2/show/NCT00410813. Accessed May 2009.
)| false
ClinicalTrials.gov. Dasatinib in combination with zoledronic acid for the treatment of breast cancer with bone metastasis. Available at: http://clinicaltrials.gov/ct2/show/NCT00566618?show_desc=Y. Accessed May 2009.
ClinicalTrials.gov. Dasatinib in combination with zoledronic acid for the treatment of breast cancer with bone metastasis. Available at: http://clinicaltrials.gov/ct2/show/NCT00566618?show_desc=Y. Accessed May 2009.
)| false
ClinicalTrials.gov. Trial of dasatinib (Sprycel®) in subjects with hormone-refractory prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00570700. Accessed May 2009.
ClinicalTrials.gov. Trial of dasatinib (Sprycel®) in subjects with hormone-refractory prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00570700. Accessed May 2009.
)| false
Le GallC, BellahceneA, BonnelyeE et al.. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res2007;67:9894–9902.
Le GallCBellahceneABonnelyeE. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007;67:9894–9902.
17942921)| false
ClinicalTrials.gov. Archive: view of NCT00692458 on 2008_12_07. Available at: http://clinicaltrials.gov/archive/NCT00692458/2008_12_07. AccessedMay 2009.
ClinicalTrials.gov. Archive: view of NCT00692458 on 2008_12_07. Available at: http://clinicaltrials.gov/archive/NCT00692458/2008_12_07. AccessedMay 2009.
)| false
MuindiJ, CoombesRC, GoldingS et al.. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol1983;56:233–236.
MuindiJCoombesRCGoldingS. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol 1983;56:233–236.
6831145)| false
DurningPBestJJSellwoodRA. Recognition of metastatic bone disease in cancer of the breast by computed tomography. Clin Oncol 1983;9:343–346.
6607147)| false
HannaSL, FletcherBD, FaircloughDL et al.. Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy. Skeletal Radiol1991;20:79–84.
HannaSLFletcherBDFaircloughDL. Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy. Skeletal Radiol 1991;20:79–84.
2020867)| false
KrishnamurthyGT, TubisM, HissJ, BlahdWH. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA1977;237:2504–2506.
KrishnamurthyGTTubisMHissJBlahdWH. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA 1977;237:2504–2506.
576963)| false
ZelinkaT, TimmersHJ, KozupaA et al.. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer2008;15:311–323.
ZelinkaTTimmersHJKozupaA. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer 2008;15:311–323.
18310297)| false
Daldrup-LinkHE, FranziusC, LinkTM et al.. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol2001;177:229–236.
Daldrup-LinkHEFranziusCLinkTM. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol 2001;177:229–236.
)| false
OhtaM, TokudaY, SuzukiY et al.. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun2001;22:875–879.
OhtaMTokudaYSuzukiY. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001;22:875–879.
11473206)| false
KaoCH, HsiehJF, TsaiSC et al.. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res2000;20:2189–2192.
KaoCHHsiehJFTsaiSC. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000;20:2189–2192.
10928175)| false
WuJS, WongR, JohnstonM et al.. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys2003;55:594–605.
WuJSWongRJohnstonM. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594–605.
12573746)| false
HartsellWF, ScottCB, BrunerDW et al.. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst2005;97:798–804.
HartsellWFScottCBBrunerDW. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798–804.
15928300)| false
van den HoutWB, van der LindenYM, SteenlandE et al.. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst2003;95:222–229.
van den HoutWBvan der LindenYMSteenlandE. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003;95:222–229.
12569144)| false
BradleyNM, HustedJ, SeyMS et al.. Review of patterns of practice and patients’ preferences in the treatment of bone metastases with palliative radiotherapy. Support Care Cancer2007;15:373–385.
BradleyNMHustedJSeyMS. Review of patterns of practice and patients’ preferences in the treatment of bone metastases with palliative radiotherapy. Support Care Cancer 2007;15:373–385.
17093915)| false
QuiltyPM, KirkD, BolgerJJ et al.. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol1994;31:33–40.
QuiltyPMKirkDBolgerJJ. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33–40.
7518932)| false
PorterAT, McEwanAJB, PoweJE et al.. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys1993;25:805–813.
PorterATMcEwanAJBPoweJE. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805–813.
8478230)| false
SartorO, ReidRH, HoskinPJ et al.. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology2004;63:940–945.
SartorOReidRHHoskinPJ. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940–945.
15134985)| false
MaxonHR, SchroderLE, HertzbergVS et al.. Rhenium-186(Sn)-HEDP for treatment of painful osseous metastases: results of a double blind crossover comparison with placebo. J Nucl Med1991;32:1877–1881.
MaxonHRSchroderLEHertzbergVS. Rhenium-186(Sn)-HEDP for treatment of painful osseous metastases: results of a double blind crossover comparison with placebo. J Nucl Med 1991;32:1877–1881.
1717669)| false
TuS, MillikanRE, MengistuB et al.. Bone targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet2001;357:336–341.
TuSMillikanREMengistuB. Bone targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336–341.
11210994)| false
RedmondBJ, BiermannJS, BlasierRB. Interlocking intramedullary nailing of pathological fractures of the shaft of the humerus. J Bone Joint Surg Am1996;78A:891–896.
RedmondBJBiermannJSBlasierRB. Interlocking intramedullary nailing of pathological fractures of the shaft of the humerus. J Bone Joint Surg Am 1996;78A:891–896.
)| false
FranckWM, OlivieriM, JannaschO, HennigFF. An expandable nailing system for the management of pathological humerus fractures. Arch Orthop Trauma Surg2002;122:400–405.
FranckWMOlivieriMJannaschOHennigFF. An expandable nailing system for the management of pathological humerus fractures. Arch Orthop Trauma Surg 2002;122:400–405.
12228801)| false
SamsaniSR, PanikkarV, VenuKM et al.. Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail. Eur J Surg Oncol2004;30:993–997.
SamsaniSRPanikkarVVenuKM. Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail. Eur J Surg Oncol 2004;30:993–997.
15498647)| false
MoholkarK, MohanR, GrigorisP. The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases. Acta Orthop Belg2004;70:429–434.
MoholkarKMohanRGrigorisP. The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases. Acta Orthop Belg 2004;70:429–434.
)| false
MarcoRA, ShethDS, BolandPJ et al.. Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am2000;82:642–651.
MarcoRAShethDSBolandPJ. Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am 2000;82:642–651.
10819275)| false
BeneveniaJ, CyranFP, BiermannJS et al.. Treatment of advanced metastatic lesions of the acetabulum using the saddle prosthesis. Clin Orthop Relat Res2004:23–31.
BeneveniaJCyranFPBiermannJS. Treatment of advanced metastatic lesions of the acetabulum using the saddle prosthesis. Clin Orthop Relat Res 2004:23–31.
15346047)| false
FourneyDR, SchomerDF, NaderR et al.. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg2003;98:21–30.
FourneyDRSchomerDFNaderR. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003;98:21–30.
12546384)| false
KelekisA, LovbladKO, MehdizadeA et al.. Pelvic osteoplasty in osteolytic metastases: technical approach under fluoroscopic guidance and early clinical results. J Vasc Interv Radiol2005;16:81–88.
CallstromMR, CharboneauJW, GoetzMP et al.. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol2006;35:1–15.
CallstromMRCharboneauJWGoetzMP. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol 2006;35:1–15.
16205922)| false
RosenLS, GordonD, TchekmedyianNS et al.. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer2004;100:2613–2621.
RosenLSGordonDTchekmedyianNS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613–2621.
15197804)| false
